Amryt Pharma (Amryt Pharma) Other Net Income (Loss) : $-0.0 Mil (TTM As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Other Net Income (Loss)?

Amryt Pharma's Other Net Income (Loss) for the three months ended in Sep. 2022 was $0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.0 Mil.

Amryt Pharma's quarterly Other Net Income (Loss) increased from Mar. 2022 ($-0.0 Mil) to Jun. 2022 ($-0.0 Mil) and increased from Jun. 2022 ($-0.0 Mil) to Sep. 2022 ($0.0 Mil).

Amryt Pharma's annual Other Net Income (Loss) declined from Dec. 2019 ($0.0 Mil) to Dec. 2020 ($0.0 Mil) but then stayed the same from Dec. 2020 ($0.0 Mil) to Dec. 2021 ($0.0 Mil).

Amryt Pharma Other Net Income (Loss) Historical Data

The historical data trend for Amryt Pharma's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Other Net Income (Loss) Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Other Net Income (Loss)

Get a 7-Day Free Trial

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Amryt Pharma Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.0 Mil.

Amryt Pharma Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).